Virtus LifeSci Biotech Products ETF holds a quantitatively derived Bronze Morningstar Medalist Rating. The rating reflects that it has scored better than the norm on factors Morningstar research associates with future outperformance relative to category peers.
Virtus LifeSci Biotech Products ETF BBP
Morningstar’s Analysis BBP
Will BBP outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 27.8
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Moderna Inc | 5.36 | 7M | Healthcare |
Iovance Biotherapeutics Inc | 4.59 | 6M | Healthcare |
Verastem Inc | 3.17 | 4M | Healthcare |
Omeros Corp | 2.57 | 3M | Healthcare |
Halozyme Therapeutics Inc | 2.38 | 3M | Healthcare |
Kiniksa Pharmaceuticals International PLC Class A | 2.21 | 3M | Healthcare |
Xeris Biopharma Holdings Inc | 1.98 | 3M | Healthcare |
Rigel Pharmaceuticals Inc | 1.98 | 3M | Healthcare |
BeOne Medicines Ltd ADR | 1.78 | 2M | Healthcare |
Precigen Inc | 1.78 | 2M | Healthcare |